Spots Global Cancer Trial Database for t cells
Every month we try and update this database with for t cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Melanoma Vaccine With Peptides and Leuprolide | NCT00254397 | Melanoma | Leuprolide GP100: 209-217(... MAGE-3 Peptide | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning | NCT00664196 | Prostate Cancer | Gene Modified T... | 18 Years - | Roger Williams Medical Center | |
| Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker | NCT01198808 | Bladder Cancer | 18 Years - 90 Years | Technical University of Munich | ||
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer | NCT00429078 | Gastric Cancer | 2nd Generation ... | 18 Years - | Roger Williams Medical Center | |
| A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome | NCT05411718 | T Cells Colorectal Canc... Lynch Syndrome | Naproxen Aspirin | 18 Years - | M.D. Anderson Cancer Center | |
| Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker | NCT01198808 | Bladder Cancer | 18 Years - 90 Years | Technical University of Munich | ||
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies | NCT00001432 | Chronic Myeloid... Healthy Hematologic Neo... Lymphoma | - | National Institutes of Health Clinical Center (CC) | ||
| Trial of Second Generation Designer T Cells in Colorectal Carcinoma | NCT00673322 | Colorectal Canc... | Gene Modified T... | 18 Years - | Roger Williams Medical Center | |
| Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas | NCT01723306 | Metastatic Canc... | Gene Modified T... | 18 Years - 80 Years | Roger Williams Medical Center | |
| Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning | NCT00664196 | Prostate Cancer | Gene Modified T... | 18 Years - | Roger Williams Medical Center | |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | NCT06218303 | Ductal Carcinom... | MUC1 Peptide Va... Hiltonol® Aromatase Inhib... | 18 Years - | University of Pittsburgh | |
| A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome | NCT00217594 | Myelodysplastic... | Alemtuzumab (Ca... | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells | NCT01373047 | Liver Metastase... | anti-CEA 2nd ge... | 18 Years - | Roger Williams Medical Center | |
| Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | NCT04146051 | Myasthenia Grav... | Descartes-08 | 18 Years - | Cartesian Therapeutics | |
| Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients | NCT00081783 | Non-Hodgkin's L... | Xcellerated T C... | 18 Years - | Xcyte Therapies | |
| Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer | NCT00673829 | Breast Cancer | Gene Modified T... Gene Modified T... | 18 Years - | Roger Williams Medical Center | |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | NCT03388632 | Metastatic Soli... Treatment-Refra... | rhIL-15 Ipilimumab Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CAR-T Cells in the Treatment of Malignant Hematological Tumors | NCT05619861 | Lymphoma, B-Cel... Leukemia, B-cel... Leukemia, T-Cel... Multiple Myelom... | CAR-T | 14 Years - 70 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| Trial of Second Generation Designer T Cells in Colorectal Carcinoma | NCT00673322 | Colorectal Canc... | Gene Modified T... | 18 Years - | Roger Williams Medical Center | |
| Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer | NCT03240861 | HLA-A*0201 Posi... Locally Advance... NY-ESO-1 Positi... Unresectable Ma... Sarcoma | 18F-FHBG Aldesleukin Busulfan Cellular Therap... Computed Tomogr... Filgrastim Fludarabine Leukapheresis Plerixafor Positron Emissi... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients | NCT05789498 | Lung Cancer Esophageal Canc... | In vitro stimul... | 18 Years - 80 Years | The First Affiliated Hospital of Soochow University | |
| Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer | NCT00673829 | Breast Cancer | Gene Modified T... Gene Modified T... | 18 Years - | Roger Williams Medical Center | |
| Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells | NCT01362452 | Leukemia Lymphoma | T-Cell Infusion Cord Blood Infu... | 1 Year - 75 Years | M.D. Anderson Cancer Center | |
| Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | NCT02498912 | Solid Tumors | Production of G... Cyclophosphamid... IP Catheter Ins... Infusion of 4H1... Fludarabine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas | NCT01723306 | Metastatic Canc... | Gene Modified T... | 18 Years - 80 Years | Roger Williams Medical Center | |
| Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | NCT00338377 | Melanoma | Dendritic Cell ... Cyclophosphamid... Fludarabine T-Cells Interleukin-2 Mesna Intrathecal T-C... Intrathecal Int... | 12 Years - | M.D. Anderson Cancer Center | |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | NCT06218303 | Ductal Carcinom... | MUC1 Peptide Va... Hiltonol® Aromatase Inhib... | 18 Years - | University of Pittsburgh | |
| Trial of Second Generation Designer T Cells in Colorectal Carcinoma | NCT00673322 | Colorectal Canc... | Gene Modified T... | 18 Years - | Roger Williams Medical Center | |
| Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers | NCT04723121 | Bladder Cancer | Urine ELISA for... Reverse transcr... | 18 Years - | Mansoura University | |
| Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients | NCT00081783 | Non-Hodgkin's L... | Xcellerated T C... | 18 Years - | Xcyte Therapies | |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | NCT02153905 | Breast Cancer Cervical Cancer Renal Cancer Melanoma Bladder Cancer | Aldesleukin Fludarabine Cyclophosphamid... Anti-MAGE-A3 hu... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma | NCT01946373 | Melanoma | Cyclophosphamid... Fludarabine T cells Interleukin-2 Dendritic cell ... | 18 Years - 74 Years | Karolinska University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
